Genitourinary Cancers Clinical Trials & Research at Providence Medical Group

Providence Medical Group is currently enrolling patients for the following genitourinary cancers clinical trials:

Urothelial Cancer
Prostate Cancer
Renal Cell Cancer

Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous Administration to Patients with Anorexia and Advanced Cancer

Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Melissa Phillips // (707) 521-3833 ext. 1313
Resources and Links:
Sponsor: Pfizer


A Study of Enfortumab Vedotin Alone or with Other Therapies for Treatment of Urothelial Cancer (EV-103)

Treatment: Enfortumab Vedotin
PI: Ian Anderson, MD
Study Coordinator: Teresa Lund // // (707) 521-3803 ext. 1103
Resources and Links:


A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON3)

Treatment agent: Rucaparib (PARPi)
PI: Wes Lee, MD
Study Coordinator: Teresa Lund // // (707) 521-3803
Resources and Links: NCT No: NCT02975934

Renal Cell

Our Providers

Our Locations